Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Heart Metabolics

Request full access

Cardiometabolic therapy for hypertrophic cardiomyopathy orphan disease

Dublin, IrelandFounded 2012Health

About Heart Metabolics

Heart Metabolics was a biopharmaceutical company focused on developing treatments for cardio-metabolic diseases, particularly hypertrophic cardiomyopathy (HCM). The company was founded in 2013 by Professor Michael Frenneaux and Dr. Houman Ashrafian, who discovered that the known drug perhexiline could potentially reverse adverse cardiac energetics and heart failure symptoms associated with HCM.

The company's primary focus was the clinical development of its lead drug candidate, perhexiline, a carnitine palmitoyl-transferase (CPT) inhibitor. Perhexiline works by shifting the heart's energy metabolism from fatty acid to glucose utilization, which is believed to improve myocardial energetics and normalize the energy imbalance caused by the genetic defects in HCM. The company's strategy was to repurpose this existing drug, which had received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in 2012 for treating moderate-to-severe heart failure in HCM patients.

In January 2013, the UK-based entity secured $4 million in a Series A round to advance U.S. clinical development. Following this, a new Irish biotechnology company, Heart Metabolics Limited, was launched in April 2014 with a $20 million Series A financing from investors including venBio, Seroba Life Sciences, Brandon Capital Partners, and AshHill. These funds were used to acquire the Phase 3-ready perhexiline candidate from the original UK company, HMBL Limited. The company reached an agreement with the FDA under a Special Protocol Assessment (SPA) for a single, pivotal Phase 3 trial. A Phase 2b study was initiated in August 2016 to further demonstrate the drug's safety and efficacy. According to Tracxn, the company is now considered deadpooled.

Source: Dealroom company data

At a glance

Status
Closed
Founded
2012
Headquarters
Dublin, Ireland
Employees
3
Open positions
None listed
Industry
Health
Sector
Health, Risk Management, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Apr 2014 $20M $80M AshHill Biomedical · Seroba Life Sciences · venBio Partners —
SERIES A✓Equity / VC Jan 2013 $4M $16M AshHill Biomedical —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearEBITDAMarginProfitMargin
2026 — —
2025 — —
2024 — —
2023 — —
2022 — —
2021 — —
2020 — —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Heart Metabolics website traffic

Latest recorded traffic for Heart Metabolics is 0 monthly website visits. Heart Metabolics's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Heart Metabolics in the Dublin ecosystem

Live from Dealroom

The Heart Metabolics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • AshHill Biomedical
  • Seroba Life Sciences
  • venBio Partners
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇮🇪 Ireland · Dublin HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Heart Metabolics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Heart Metabolics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.